Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF levels of Aβ and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neurodegenerative pathology, but more disease specific information can be gleaned from assessment of the specific post-translational modifications of tau [37,59].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 4×
“…biomarker compared with its measurement in CSF. Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with accuracy change on Aβ42/40 ratio detected in CSF and associates with measures of brain amyloid plaques by amyloid PET scans (Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).”
BackgroundMethodInfluentialSelf-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Cited by
Items 101–200 of 476
Tau Toxicity in Neurodegeneration
Liang, S., Wang, Z.-T., Tan, L., & Yu, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02809-3 · Cited by 64
“The change in p-tau-217 in plasma can reflect the phosphorylation of soluble tau proteins, which has potential value in the detection of AD pathology and the diagnosis of AD [115].”
BackgroundCummings, J. L., & Kinney, J. W. (2022) · Medicina · doi:10.3390/medicina58070952 · Cited by 64
“Plasma levels of phospho-tau (p-tau) 181 and p-tau 217 are elevated in patients with amyloid plaques and appear to be measures of plaque-related neuritic changes [26].”
BackgroundA Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes
Pao, P., Seo, J., Lee, A., Kritskiy, O., Patnaik, D., Penney, J., Raju, R. M., Geigenmüller, U., Silva, M. C., Lucente, D. E., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217864120 · Cited by 64
“Higher levels of plasma pTau T181 correlate with worse cognition in patients with AD and have been suggested as a reliable biomarker for AD (46).”
Alber, J., Bouwman, F. H., den Haan, J., Rissman, R. A., Groef, L. D., Koronyo‐Hamaoui, M., Lengyel, I., & Thal, D. R. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13529 · Cited by 65
“9,13,14 Inaddition, plasma biomarkers lack the spatial information on the site of neuronal and vascular injury and can be influenced by interference from peripheral tissue, as well as inflammatory and metabolic processes.”
BackgroundThe anesthetic sevoflurane induces tau trafficking from neurons to microglia
Dong, Y., Liang, F., Huang, L., Fang, F., Yang, G., Tanzi, R. E., Zhang, Y., Quan, Q., & Xie, Z. (2021) · Communications Biology · doi:10.1038/s42003-021-02047-8 · Cited by 58
McDade, E. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001131 · Cited by 64
Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges
Delaby, C., Hirtz, C., & Lehmann, S. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.09.003 · Cited by 65
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
Doré, V., Doecke, J. D., Saad, Z. S., Triana‐Baltzer, G., Slemmon, R., Krishnadas, N., Bourgeat, P., Huang, K., Burnham, S., Fowler, C., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12307 · Cited by 59
Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
Teunissen, C. E., Kimble, L. E., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., José, N. G. D. S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100629 · Cited by 63
“SISCAPA-MS differs from the conventional IP-MS work fl ow by fi rst digesting the proteins, followed by capturing proteotypic peptides using antipeptide antibodies.”
BackgroundMethodInfluentialProteoforms and their expanding role in laboratory medicine
Forgrave, L. M., Wang, M., Yang, D., & DeMarco, M. L. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00260 · Cited by 62
“For example, a PRM method found that the plasma tau proteoforms phosphorylated at T217 had the highest diagnostic performance among a group of phophorylation sites tested [128].”
MethodZetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 61
Llano, D. A., Initiative, A. D. N., & Devanarayan, V. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201420 · Cited by 61
Longitudinal Speech Biomarkers for Automated Alzheimer's Detection
Laguarta, J., Hueto, F., Rajasekaran, P., Sarma, S. E., & Subirana, B. (2021) · Frontiers in Computer Science · doi:10.3389/fcomp.2021.624694 · Cited by 60
“…signs of AD onset in the human body come in the form of recent research on blood plasma phosphorylated-tau isoforms diagnostic biomarkers demonstrating chemical traces of dementia, and of AD in particular, decades in advance of clinical diagnosis (Barthélemy et al., 2020; Palmqvist et al., 2020).”
BackgroundDiagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León‐Arcia, K., Llibre‐Guerra, J. J., Berlanga‐Acosta, J., Baez, S. D. L. C., Guillén, G. E., & Valdes-Sosa, P. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.683689 · Cited by 60
Montoliu‐Gaya, L., Alosco, M. L., Yhang, E., Tripodis, Y., Sconzo, D., Ally, M., Grötschel, L., Ashton, N. J., Lantero‐Rodriguez, J., Sauer, M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02660-3 · Cited by 60
“Mass spectrometry (MS) allows for increased specificity for detection of low abundant proteins and can quantify numerous p-tau epitopes simultaneously in a single acquisition [3, 18].”
BackgroundCellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
Wennström, M., Janelidze, S., Nilsson, K. P. R., Bank, T. N. B., Serrano, G. E., Beach, T. G., Dage, J. L., & Hansson, O. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01307-2 · Cited by 59
“This idea is supported, not only by previous studies demonstrating strong correlations between levels of p-tau217 and various p-tau variants in plasma and CSF [4, 10, 11, 19, 20] but also by a recently published study showing that p-tau217 can be found in the same early tangle maturation stages as many of the other p-…”
ResultFluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Domínguez-Fernández, C., Egiguren-Ortiz, J., Razquin, J., Gómez-Galán, M., Heras-García, L. D. L., Paredes-Rodriguez, E., Astigarraga, E., Miguélez, C., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043321 · Cited by 62
“pTau181 has also been shown to be able to differentiate between patients with mild cognitive impairment who progress to AD and those who do not progress to AD [70,73].”
BackgroundZhang, L., Su, Y., Liang, X., Cao, K., Luo, Q., & Luo, H. (2023) · Nano Research · doi:10.1007/s12274-022-5354-4 · Cited by 59
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Cognitive impairment and World Trade Centre-related exposures
Clouston, S., Hall, C. B., Kritikos, M., Bennett, D. A., DeKosky, S. T., Edwards, J. D., Finch, C. E., Kreisl, W. C., Mielke, M. M., Peskind, E. R., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00576-8 · Cited by 56
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Mielke, M. M., Aakre, J. A., Algeciras‐Schimnich, A., Proctor, N. K., Machulda, M. M., Eichenlaub, U., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Jack, C. R., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12415 · Cited by 55
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
Snellman, A., Lantero-Rodriguez, J., Emeršič, A., Vrillon, A., Karikari, T. K., Ashton, N. J., Gregorič Kramberger, M., Čučnik, S., Paquet, C., Rot, U., et al. (2022) · Brain · doi:10.1093/brain/awab481 · Cited by 51
“19,22,23 This knowledge has been applied to develop new p-tau immunoas-says for use in blood, targeting different epitopes than the validated assays.”
Aguillon, D., Langella, S., Chen, Y., Sanchez, J. S., Su, Y., Vila‐Castelar, C., Vasquez, D., Zetterberg, H., Hansson, O., Dage, J. L., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12906 · Cited by 54
Duan, W., Zhou, G. D., Balachandrasekaran, A., Bhumkar, A. B., Boraste, P. B., Becker, J. T., Kuller, L. H., López, O. L., Gach, H. M., & Dai, W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210199 · Cited by 54
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01116-2 · Cited by 54
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
“Several different P-tau species can be quantified in CSF and plasma, including P-tau181 and P-tau217, and recently also other species such as P-tau231 and P-tau235 and plasma P-tau accurately predict progression to AD dementia in individuals with memory complaints [122,123].”
BackgroundImpact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease
Kurz, C., Stöckl, L., Schrurs, I., Suridjan, I., Guersel, S., Bittner, T., Jethwa, A., & Perneczky, R. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15757 · Cited by 52
Rissman, R. A., Donohue, M., Langford, O., Raman, R., Abdel‐Latif, S., Yaari, R., Holdridge, K. C., Sims, J. R., Molina‐Henry, D. P., Jimenez‐Maggiora, G. A., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.134 · Cited by 53
“MS-based P-tau217 studies have found similar AUC values to what we report here but require somewhat complicated algorithms that include additional variables such as non-phosphorylated tau217, age, BMI and APOE ε4 (35).”
Cano, A. C., Capdevila, M., Puerta, R., Arranz, J., Montrreal, L., de Rojas, I., García‐González, P., Olivé, C., García‐Gutiérrez, F., Sotolongo‐Grau, Ó., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105345 · Cited by 53
“Ourresults con fi rmed that plasma pTau181 correlated with CSF pTau181 in both MCI and AD dementia, in agreement with previous studies, 10,20,36 but not in subjects with SCD and other dementias, which Fig.”
Fowler, C. J., Stoops, E., Rainey‐Smith, S. R., Vanmechelen, E., Vanbrabant, J., Dewit, N., Mauroo, K., Maruff, P. T., Rowe, C. C., Fripp, J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12375 · Cited by 50
Pahlke, S. C., Kahale, L. A., Mahinrad, S., Sousa‐Pinto, B., Vieira, R. J., McAteer, M. B., Claessen, T., Contador, J., Hofmann, A., Kuchenbecker, L. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70828 · Cited by 51
Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 47
“404 J Clin Neurol 2022;18(4):401-409 Promising Blood Biomarkers in Alzheimer’s Disease JCN”
BackgroundInfluentialAdvances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
Non-invasive Biomarkers for Early Detection of Alzheimer’s Disease: a New-Age Perspective
Chimthanawala, N. M. A., Haria, A., & Sathaye, S. S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03578-3 · Cited by 47
“Concerning p-tau217, Barthelemy et al. showed that varied phosphorylation profiles of soluble tau in blood plasma and CSF in connection with amyloidosis act as a distinguishing feature between the stages of AD [17].”
InfluentialLantero-Rodriguez, J., Salvadó, G., Snellman, A., Montoliu-Gaya, L., Brum, W. S., Benedet, A. L., Mattsson-Carlgren, N., Tideman, P., Janelidze, S., Palmqvist, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00707-x · Cited by 41
Wilczyńska, K., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113452 · Cited by 43
“Hyperphosphorylated tau protein and its isoforms, such as p-tau-217, measured in the peripheral blood are also promising AD biomarker candidates [35].”
BackgroundCurrent research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis
Feng, L., Li, J., & Zhang, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101492 · Cited by 47
Fluid and Biopsy Based Biomarkers in Parkinson's Disease
Coughlin, D. G., & Irwin, D. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01379-z · Cited by 49
ADNI Biomarker Core: A review of progress since 2004 and future challenges
Shaw, L. M. J., Korecka, M., Lee, E. B., Cousins, K. A. Q., Vanderstichele, H., Schindler, S. E., Tosun, D., DeMarco, M. L., Brylska, M., Wan, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14264 · Cited by 48
Synapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 47
Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications
Azevedo, R., Jacquemin, C., Villain, N., Fenaille, F., Lamari, F., & Bécher, F. (2022) · Cells · doi:10.3390/cells11081279 · Cited by 46
“pT217 and pT181 in plasma were highly specific for amyloid plaque pathology [85].”
BackgroundInfluentialAmyloid-β Oligomers: Multiple Moving Targets
Shea, D. W., & Daggett, V. (2022) · Biophysica · doi:10.3390/biophysica2020010 · Cited by 46
Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia
Schindler, S. E., & Bateman, R. J. (2021) · Nature Aging · doi:10.1038/s43587-020-00008-0 · Cited by 46
Self-citationHirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 46
Min, J., Rouanet, J. P., Martini, A. C., Nashiro, K., Yoo, H. J., Porat, S., Cho, C., Wan, J., Cole, S. W., Head, E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30167-0 · Cited by 46
González‐Ortiz, F., Dulewicz, M., Ashton, N. J., Kac, P. R., Zetterberg, H., Andersson, E., Yakoub, Y., Hanrieder, J., Turton, M., Harrison, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.21554 · Cited by 45
Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies
Diaz‐Galvan, P., Przybelski, S. A., Algeciras‐Schimnich, A., Figdore, D. J., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13653 · Cited by 43
Biomarkers for Managing Neurodegenerative Diseases
Cheslow, L., Snook, A. E., & Waldman, S. A. (2024) · Biomolecules · doi:10.3390/biom14040398 · Cited by 44
“P-tau217 may be even more accurate than p-tau181 at predicting A β -PET positivity, correlating with tau-PET [25], and correctly differentiating AD from other forms of dementia in CSF and plasma in up to 96% of cases [26–28].”
MethodJarek, D. J., Mizerka, H., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2024) · Biomedicines · doi:10.3390/biomedicines12040786 · Cited by 43
“These findings support the thesis that the p-tau217/tau217 ratio reasonably distinguishes A β + and A β − CU, whereas the p-tau181/tau181 ratio is not so accurate [79].”
BackgroundResultInfluentialModeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 42
“4,5 For example, plasma p-tau has been shown to increase with disease severity and predict cognitive decline in AD 6–11 as well as differentiate AD patients from those with cognitive impairment secondary to other tauopathies.”
BackgroundPhenotyping Alzheimer's disease with blood tests
Blennow, K. (2021) · Science · doi:10.1126/science.abi5208 · Cited by 41
Böken, D., Cox, D., Burke, M., Lam, J. Y. L., Katsinelos, T., Danial, J. S. H., Fertan, E., McEwan, W. A., Rowe, J. B., & Klenerman, D. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202317756 · Cited by 43
Frank, B. E., Ally, M., Brekke, B., Zetterberg, H., Blennow, K., Sugarman, M. A., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12508 · Cited by 42
“3,24 Plasma p-tau 181 concentration is associated with worse neuropsychological test performance, 25,26 correlates with longitudinal grey matter atrophy and increased odds of conversion to AD dementia, 17,25,27–30 and distinguishes AD dementia from other neurodegenerative disorders (e.g.,…”
Hyman, B. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-023749 · Cited by 39
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression
Dincer, A., Chen, C. D., McKay, N. S., Koenig, L. N., McCullough, A. A., Flores, S. E., Keefe, S., Schultz, S. A., Feldman, R. L., Joseph‐Mathurin, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7646 · Cited by 40
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38
Self-citationTraub, J., Otto, M., Sell, R., Göpfert, D., Homola, G. A., Steinacker, P., Oeckl, P., Morbach, C., Frantz, S., Pham, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01087-4 · Cited by 38
“pTau emerged as a plasma and serum biomarker of cerebral tau and amyloid pathologies, which are hallmarks of AD [14, 15].”
BackgroundWojdała, A. L., Vanbrabant, J., Bayoumy, S., Antwi‐Berko, D., Bastard, N. L., van der Flier, W. M., Jeromin, A., Lambrechts, C., Loo, M. V., Vandijck, M. L. J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01630-5 · Cited by 38
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 38
“However, plasma p-Tau 217 has been shown to outperform plasma p-Tau 181 due to its large dynamic range and higher fold difference between AD and healthy controls [79, 80].”
Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease
Casciano, F., Zauli, E., Celeghini, C., Caruso, L., Gonelli, A., Zauli, G., & Pignatelli, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031689 · Cited by 38
“…in the development of novel biomarkers to predict neurodegeneration are still necessary, and retinal examination holds promise as a non-invasive, cost-effective, and easily accessible tool compared with neuroimaging of the central nervous system and cerebrospinal fluid analysis [256–258].”
BackgroundMethodTransferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer’s Disease
Hoshi, K., Ito, H., Abe, E., Fuwa, T. J., Kanno, M., Murakami, Y., Abe, M., Murakami, T., Yoshihara, A., Ugawa, Y., et al. (2021) · Metabolites · doi:10.3390/metabo11090616 · Cited by 37
“Current trials aimed at quantifying plasma p-tau offer promise as laboratory tests [23,24].”
BackgroundAntonioni, A., Raho, E. M., Lorenzo, F. D., Manzoli, L., Flacco, M. E., & Koch, G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12996-3 · Cited by 36
“Interestingly, two studies employed a novel approach, implementing a mass spectrometry assay technique either alone (namely, WashU) [15] or in combination with immunoprecipitation (IP-MS) [24], respectively.”
InfluentialHubbard, E. E., Heil, L. R., Merrihew, G. E., Chhatwal, J. P., Farlow, M. R., McLean, C., Ghetti, B. F., Newell, K. L., Frosch, M. P., Bateman, R. J., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00558 · Cited by 36
“10,11 In addition, there are many other pathologic changes that accompany AD, including other aggregated deposits such as Lewy bodies, 12 vascular disease, 13 energy deficiency, 14 and lysosomal storage.”
Self-citationWang, Q., Chen, Y., Readhead, B. P., Chen, K., Su, Y., Reiman, E. M., & Dudley, J. T. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00984-5 · Cited by 35
“Accurate, minimally invasive and timely diagnosis of probable AD in living individuals has always been challenging, although most recently great breakthroughs are being made in blood-based biomarkers, such as p-tau181 [32] and p-tau217 [40, 41].”
BackgroundKulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Незнанов, Н. Г., Chernoff, Y. O., & Rubel, A. A. (2021) · Prion · doi:10.1080/19336896.2021.1917289 · Cited by 35
Barthélemy, N. R., Toth, B., Manser, P. T., Bohorquez, S. M. S., Teng, E., Keeley, M., Bateman, R. J., Weimer, R. M., & Wildsmith, K. R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210677 · Cited by 36
“A recent study confirmed better performance of p-tau/u-tau ratio on T217 levels in plasma for predicting amyloid load [33].”
Self-citationWojdała, A. L., Bellomo, G., Gaetani, L., Teunissen, C. E., Parnetti, L., & Chiasserini, D. (2025) · Nature Communications · doi:10.1038/s41467-024-54878-8 · Cited by 34
“AD-dem(AUC =0.964, 95% CI 0.898 – 1.000) (Supplementary Table 15, 16).”
InfluentialP-tau217 in Alzheimer’s disease
Telser, J., Risch, L., Saely, C. H., Grossmann, K., & Werner, P. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.018 · Cited by 33
Kononikhin, A. S., Zakharova, N. V., Semenov, S. D., Bugrova, A. E., Brzhozovskiy, A. G., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Strelnikova, P. A., Ikonnikova, A. Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147907 · Cited by 34
“An improved analytical sensitivity has made it possible to measure the blood levels of other markers of AD, tau/p-tau proteins and neurofilament light (NfL) [23,24].”
BackgroundAlzheimer’s disease: From basic science to precision medicine approach
Forloni, G. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000079 · Cited by 33
Plasma Biomarkers of Traumatic Brain Injury in Adolescents With Sport-Related Concussion
Tabor, J., Penner, L. C., Galarneau, J.-M. F., Josafatow, N., Cooper, J. G., Ghodsi, M., Huang, J. W., Fraser, D. D., Smirl, J. D., Esser, M. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.31959 · Cited by 33
Central Nervous System Pericytes Contribute to Health and Disease
Girolamo, F., Errede, M., Bizzoca, A., Virgintino, D., & Ribatti, D. (2022) · Cells · doi:10.3390/cells11101707 · Cited by 33
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Bali, D., Hansson, O., & Janelidze, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01391-1 · Cited by 32
Fluid Biomarkers in Dementia Diagnosis
Schindler, S. E. (2022) · Continuum · doi:10.1212/con.0000000000001083 · Cited by 31
Li, Z., Fan, Z., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230799 · Cited by 30
Shi, L., Buckley, N. J., Bos, I., Engelborghs, S., Sleegers, K., Frisoni, G. B., Wallin, A., Lleó, A., Popp, J., Martínez‐Lage, P., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.712545 · Cited by 29
Afrin, M. R., Upadhyaya, P. G., Hashim, A., Bhattacharya, K., Chanu, N. R., Das, D., Khanal, P., & Deka, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102736 · Cited by 28
Tau proteins in blood as biomarkers of Alzheimer’s disease and other proteinopathies
Verde, F. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02471-y · Cited by 28
“on two BioFINDER cohorts with total n = 526 individuals, indicated that the correlation between plasma and CSF P-tau181 was only valid for Aβ-positive subjects and not for Aβ-negative ones (Barthélemy et al. 2020; Janelidze et al. 2020a).”
BackgroundComorbidities confound Alzheimer’s blood tests
Schindler, S. E., & Karikari, T. K. (2022) · Nature Medicine · doi:10.1038/s41591-022-01875-3 · Cited by 27
Mozersky, J. T., Hartz, S. M., Linnenbringer, E. L., Levin, L., Streitz, M. L., Stock, K., Moulder, K. L., & Morris, J. C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200993 · Cited by 28
“Recent discoveries regarding blood-based biomarker tests [7, 8] could significantly speed the transition of biomarker testing to clinical care given the potential to reduce burden and cost when such a test becomes available.”
Provost, K., Iaccarino, L., Soleimani‐Meigooni, D. N., Baker, S. L., Edwards, L., Eichenlaub, U., Hansson, O., Jagust, W. J., Janabi, M., Joie, R. L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05152-8 · Cited by 27
McGuigan, S., Evered, L. A., Scott, D. A., SILBERT, B. S., Zetterberg, H., & Blennow, K. (2021) · Medical Gas Research · doi:10.4103/2045-9912.324591 · Cited by 28
Manolopoulos, A., Delgado‐Peraza, F., Mustapić, M., Pucha, K. A., Nogueras‐Ortiz, C. J., Daskalopoulos, A., Knight, D. D., Leoutsakos, J., Oh, E. S., Lyketsos, C. G., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1254834 · Cited by 28
Garbarino, V. R., Palavicini, J. P., Melendez, J., Barthelemy, N. R., He, Y., Kautz, T. F., Lopez-Cruzan, M., Mathews, J. J., Xu, P., Zhang, B., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00591 · Cited by 26
“CSF levels of A β and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neuro-degenerative pathology, but more disease speci fi c information can be gleaned from assessment of the speci fi c post-translational modi fi cations of tau [37,59].”
Self-citationFluid biomarkers for neurodegenerative diseases: a comprehensive update
Valletta, M., Briel, N., Yuksekel, I., Barboure, M. C., Coward, A. R., Houwer, J. F. H. D., Fawad, A., González-Mayoral, A., Iaccarino, G., Martínez‐Dubarbie, F., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01919-z · Cited by 26
Wang, J., Lu, X., & He, Y. (2025) · Biosensors · doi:10.3390/bios15020085 · Cited by 26
“…offers advantages like lower invasiveness, accessibility, and reduced costs compared to PET imaging or lumbar puncture [16], detecting these markers in blood remains challenging due to their extremely low concentrations and the difficulty of distinguishing pathological from normal states [50].”
Lussier, F. Z., Benedet, A. L., Therriault, J., Pascoal, T. A., Tissot, C., Chamoun, M., Mathotaarachchi, S. S., Savard, M., Ashton, N. J., Karikari, T. K., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab073 · Cited by 26
“plasma and serum) using ultrasensitive immunoassays and mass spectrometry methods.(15) Plasma p-tau181 levels have been shown to be strongly associated with brain tau pathology, significantly elevated in Alzheimer’s disease and differentiate the disease from other neurodegenerative disorders.”
MethodGiampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 25
“Recent data support the promising role of p-tau217 as a specific indicator of AD pathology when also detected in plasma [40,41] (Table 1).”
BackgroundResultWang, Z., Tan, L., Gao, P., Ma, Y., Fu, Y., Sun, Y., Yu, J., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13413 · Cited by 25
“43,44 Therefore, comprehending the impact of these comorbidities on plasma levels is also crucial for their prospective interpretation in the context of clinical screening, diagnosis, or prognosis at the population level.”
BackgroundIntegrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders
Li, C., Chen, T., Chiu, M., Yen, R., Shih, M., & Lin, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.646440 · Cited by 26
“A blood-based tau assay has recently emerged because of blood’s easy accessibility for repeated measurement (Barthélemy et al., 2020).”
BackgroundBiomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
Li, T.-R., Yang, Q. Z., Hu, X., & Han, Y. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210524153901 · Cited by 24
“Notably, plasma p-tau217 also had the ability to distinguish preclinical patients from amyloidnegative cognitively intact individuals [109, 117, 118], and among gene mutation patients who inevitably develop clinically manifested AD, it has already significantly increased 20 years before the onset of symptoms [118].”
InfluentialHyperphosphorylated Tau Inflicts Intracellular Stress Responses that Are Mitigated by Apomorphine
Song, Z., Wang, K., Hagar, H. C., Chen, H., Kuan, C.-Y., Zhang, K., & Kuo, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03689-x · Cited by 24
“In addition to significant overlapping with disease-related phosphorylation sites such as T181 and T217 [63, 78], the stoichiometry of phosphorylation (estimated to be 11–14 phosphate per tau molecule, Supplemental Figure 2) also is consistent with that in the disease [10].”
Guo, Z., Tian, C., Shi, Y., Song, X., Yin, W., Tao, Q., Liu, J., Peng, G.-P., Wu, Z., Wang, Y., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01727-w · Cited by 24
“Plasma pTau217 and pTau181 have also been measured in other neurodegenerative diseases, in addition to AD [4, 30, 32, 33, 35, 44].”
BackgroundWang, S., Kang, D. W., Um, Y. H., Kim, S., Lee, C. U., Scheltens, P., & Lim, H. K. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01400-3 · Cited by 24
Antonioni, A., Raho, E. M., Manzoli, L., Koch, G., Flacco, M. E., & Lorenzo, F. D. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70068 · Cited by 24
Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains
Mukherjee, S., Dubois, C., Perez, K. A., Varghese, S., Birchall, I. E., Leckey, M., Davydova, N., McLean, C., Nisbet, R. M., Roberts, B. R., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15713 · Cited by 24
“Notably, the biofluid (CSF and plasma) values of p- tau increase years in advance of the tau- PET signal (Barthélemy et al., 2020).”
BackgroundLombardi, G., Pancani, S., Manca, R., Mitolo, M., Baiardi, S., Massa, F., Coppola, L., Franzese, M., Nicolai, E., Guerini, F. R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312916 · Cited by 23
Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease
Thijssen, E. H., & Rabinovici, G. D. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4200 · Cited by 23
Campese, N., Palermo, G., Gamba, C. D., Beatino, M. F., Galgani, A., Belli, E., Prete, E. D., Vecchia, A. D., Vergallo, A., Siciliano, G., et al. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1886929 · Cited by 23
Metadata
- Authors
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Barthélemy, Nicolas R.
- Bateman, Randall J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-28
- Volume
- 217
- Issue
- 11
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7596823
- OpenAlex
- W3045987239
- Cited by
- 437
- References
- 36
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alzheimer’s Association (AARF-16-443265)
- Rainwater Charitable Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- Tau SILK Consortium
- AbbVie
- Biogen
- Eli Lilly and Company
- Coins for Alzheimer’s Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.